This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • Longer-term data for Yescarta in r/r follicular ly...

Longer-term data for Yescarta in r/r follicular lymphoma demonstrates substantial survival improvement over current therapies .- Kite/Gilead Sciences

Read time: 1 mins
Published:14th Jun 2021
Kite, a Gilead Company announced follow-up results from the pivotal ZUMA-5 trial of Yescarta (axicabtagene ciloleucel) – the first and only CAR T-cell therapy approved in patients with relapsed or refractory indolent follicular lymphoma (FL). At a minimum follow-up of 18 months, 94% of patients had achieved a response, and secondary endpoints of median progression-free survival (PFS) and overall survival (OS) were not yet reached.

In a weighted analysis comparing ZUMA-5 patients with a minimum of 18 months follow-up with those observed in SCHOLAR-5, an external control cohort, Yescarta demonstrated superior OS and PFS over currently available treatments. These data were presented as a part of a late-breaking session at the 26th Annual Meeting of the European Hematology Association (EHA2021) taking place virtually this year from June 9-17 (Abstract #LB1904). The propensity score analysis compared follow-up data (median follow-up of 23.3 months; in at least 80 patients with FL) from the pivotal Phase II ZUMA-5 study (n=86) to a weighted sample from the SCHOLAR-5 external control cohort of current therapies (n=85), balanced for patient characteristics through propensity scoring. Ninety-four percent of patients in the ZUMA-5 cohort achieved a response compared to 50% of patients in the control cohort (median follow-up of 26.2 months), with an odds ratio of 16.2 (95% confidence interval [CI]: 5.6-46.9). Yescarta demonstrated a 58% reduction in the risk of death (HR: 0.42; 95% CI: 0.21-0.83, p=0.01) and 70% reduction in the risk of disease progression, relapse or death (HR: 0.30; 95% CI: 0.18-0.49, p<0.001) versus current therapies in the control cohort. while median os and pfs were both not reached in zuma-5, median pfs and os were 12.7 months and 59.8 months, respectively, in the control cohort. in the zuma-5 safety analysis set (n="146)," grade 3 or higher cytokine release syndrome (crs) and neurologic toxicities occurred in 8% and 21% of patients, respectively.></0.001)>

Condition: Follicular + Marginal Zone Lymphoma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.